Early drug treatment may stop NF1 tumors before they cause harm
NCT ID NCT06188741
First seen Sep 30, 2025 · Last updated May 05, 2026 · Updated 26 times
Summary
This study tests whether giving selumetinib early to children with NF1 (ages 1 to 8) can prevent nerve tumors from growing and causing serious problems like blindness or nerve damage. About 200 children with no current symptoms but tumors in risky locations will either receive selumetinib or be observed. The goal is to see if early treatment improves tumor-free survival and reduces long-term complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Children's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Childrens of Alabama
RECRUITINGBirmingham, Alabama, 35233, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cincinnati Childrens Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229-, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21231, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Cancer Institute/ National Institutes of Health
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Riley Hospital for Children/Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Chicago
RECRUITINGChicago, Illinois, 63637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas, Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.